Published in Eur J Nucl Med Mol Imaging on February 06, 2010
The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther (2012) 1.18
The use of the NIS reporter gene for optimizing oncolytic virotherapy. Expert Opin Biol Ther (2015) 0.91
A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice. Mol Ther (2012) 0.90
SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I. PLoS One (2012) 0.89
Theranostic potential of oncolytic vaccinia virus. Theranostics (2012) 0.86
Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNIS. Mol Ther (2011) 0.83
Normalisation to blood activity is required for the accurate quantification of Na/I symporter ectopic expression by SPECT/CT in individual subjects. PLoS One (2012) 0.80
⁹⁹mTcO₄--, auger-mediated thyroid stunning: dosimetric requirements and associated molecular events. PLoS One (2014) 0.80
Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene. Mol Ther (2016) 0.76
Molecular imaging of oncolytic viral therapy. Mol Ther Oncolytics (2015) 0.76
Adrenal gland infection by serotype 5 adenovirus requires coagulation factors. PLoS One (2013) 0.76
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
Packaging capacity and stability of human adenovirus type 5 vectors. J Virol (1993) 2.76
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther (2008) 1.67
Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res (2000) 1.43
A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol (1997) 1.42
Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther (2002) 1.39
Human reporter genes: potential use in clinical studies. Nucl Med Biol (2007) 1.33
Molecular imaging of gene therapy for cancer. Gene Ther (2004) 1.28
The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med (2004) 1.22
Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther (2006) 1.17
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15
Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene (2007) 1.15
Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol (2003) 1.13
SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther (2007) 1.10
Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther (2004) 1.08
Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res (2009) 1.04
Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. Br J Pharmacol (2009) 1.01
Adenovirus-based cancer gene therapy. Curr Gene Ther (2005) 1.00
Herpes simplex virus thymidine kinase-mediated suicide gene therapy using nano/microbubbles and ultrasound. Ultrasound Med Biol (2007) 0.99
Advances in oncolytic viral therapy. Curr Opin Investig Drugs (2006) 0.97
Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res (2006) 0.96
Imaging of metastatic pulmonary tumors following NIS gene transfer using single photon emission computed tomography. Cancer Gene Ther (2004) 0.93
Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol (2007) 0.93
Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res (2009) 0.92
Real-time in vivo monitoring of viable stem cells implanted on biocompatible scaffolds. Eur J Nucl Med Mol Imaging (2008) 0.90
Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res (2004) 0.90
Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res (2004) 0.90
Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med (2007) 0.89
99mTc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression. Nucl Med Biol (2006) 0.88
A photosensitising adenovirus for photodynamic therapy. Gene Ther (1999) 0.88
In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol (2009) 0.88
In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter. Cancer Biol Ther (2007) 0.87
Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res (2008) 0.85
Adenovirus virion stability and the viral genome: size matters. Mol Ther (2009) 0.84
Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes. Hum Gene Ther (2004) 0.83
Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes. J Nucl Med (2008) 0.82
Copy number-dependent expression of a YAC-cloned human CFTR gene in a human epithelial cell line. Gene Ther (1997) 0.82
Targeting sodium/iodide symporter gene expression for estrogen-regulated imaging and therapy in breast cancer. Cancer Gene Ther (2008) 0.79
HSP70-inducible hNIS-IRES-eGFP reporter imaging: response to heat shock. Mol Imaging (2007) 0.78
Evidence that myocardial Na/I symporter gene imaging does not perturb cardiac function. J Nucl Med (2006) 0.78
In Vivo Noninvasive Imaging for Gene Therapy. J Biomed Biotechnol (2003) 0.77
Therapeutic potential of replication-selective oncolytic adenoviruses on cells from familial and sporadic desmoid tumors. Clin Cancer Res (2008) 0.76
A new transgenic mouse line to image chemically induced p53 activation in vivo. Cancer Sci (2008) 0.76
Visualization of endogenous p53-mediated transcription in vivo using sodium iodide symporter. Clin Cancer Res (2005) 0.76
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 7.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol (2011) 1.82
Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res (2010) 1.63
Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom - a web-based survey. Oral Oncol (2011) 1.58
Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev (2009) 1.58
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 1.56
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys (2010) 1.55
Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys (2006) 1.53
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50
Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer (2007) 1.44
99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med (2002) 1.44
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol (2005) 1.42
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res (2002) 1.42
Should the treatment paradigms for oral and oropharyngeal cancers be changed now: the role of human papilloma virus? ANZ J Surg (2011) 1.40
Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther (2002) 1.39
mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer Res (2005) 1.35
S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res (2007) 1.33
Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev (2005) 1.31
Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer (2010) 1.29
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets (2010) 1.25
Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol (2003) 1.19
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res (2002) 1.13
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol (2005) 1.10
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer (2012) 1.09
Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin. Cancer Sci (2008) 1.08
Head and neck cancer in the elderly: an overview on the treatment modalities. Cancer Treat Rev (2008) 1.08
Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther (2004) 1.08
The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol (2012) 1.07
Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol (2013) 1.05
Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res (2009) 1.04
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol (2012) 1.03
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer (2014) 1.03
Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. Br J Pharmacol (2009) 1.01
Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther (2013) 1.01
Clear cell carcinoma of ovary and uterus. Curr Oncol Rep (2013) 1.00
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther (2002) 1.00
Validation of the Sydney Swallow Questionnaire (SSQ) in a cohort of head and neck cancer patients. Oral Oncol (2010) 0.99
Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Res (2008) 0.99
Herpes simplex virus thymidine kinase-mediated suicide gene therapy using nano/microbubbles and ultrasound. Ultrasound Med Biol (2007) 0.99
Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther (2008) 0.99
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One (2012) 0.98
Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol (2007) 0.98
Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat (2012) 0.97
Comprehensive review of small bowel metastasis from head and neck squamous cell carcinoma. Oral Oncol (2010) 0.97
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol (2009) 0.97
Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial. Radiother Oncol (2012) 0.97
Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol (2011) 0.96
Assessment of a customised immobilisation system for head and neck IMRT using electronic portal imaging. Radiother Oncol (2005) 0.96
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer (2012) 0.95
The value of magnetic resonance imaging in target volume delineation of base of tongue tumours--a study using flexible surface coils. Radiother Oncol (2010) 0.94
A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading. Int J Radiat Oncol Biol Phys (2006) 0.94
Swallowing outcomes following Intensity Modulated Radiation Therapy (IMRT) for head & neck cancer - a systematic review. Oral Oncol (2010) 0.94
Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol (2009) 0.93
Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Res (2012) 0.93
Dose-response analysis of parotid gland function: what is the best measure of xerostomia? Radiother Oncol (2013) 0.93
Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. J Immunol (2007) 0.93
Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer. Radiother Oncol (2009) 0.93
Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int J Radiat Oncol Biol Phys (2012) 0.93
Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev (2009) 0.92
Tracheo-oesophageal party wall thickness in laryngectomised patients in India: implications for surgical voice restoration. J Surg Oncol (2010) 0.92
Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res (2009) 0.92
Immunotherapeutic potential of oncolytic virotherapy. Lancet Oncol (2008) 0.92
A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol (2007) 0.92
Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivo effects on migration capacity and tumor growth. BMC Med (2013) 0.92
Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging. Cancer Res (2006) 0.92
Oncolytic viruses in radiation oncology. Radiother Oncol (2011) 0.92
Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx. Radiother Oncol (2004) 0.92
Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res (2007) 0.92
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther (2015) 0.92
Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma. Med Dosim (2008) 0.91
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol Biol Phys (2011) 0.90
Delivery of Na/I symporter gene into skeletal muscle using nanobubbles and ultrasound: visualization of gene expression by PET. J Nucl Med (2010) 0.90
Electroglottographic comparison of voice outcomes in patients with advanced laryngopharyngeal cancer treated by chemoradiotherapy or total laryngectomy. Int J Radiat Oncol Biol Phys (2007) 0.90
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets (2005) 0.90
Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Mol Ther (2012) 0.90
Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. Radiother Oncol (2012) 0.90
Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res (2004) 0.90
Targeting HOX transcription factors in prostate cancer. BMC Urol (2014) 0.89